Surprising Health Benefits of GLP-1 Drugs

If you started looking into Ozempic or Wegovy because you wanted to lose weight, you're not alone. But the science emerging around GLP-1 receptor agonists tells a much bigger story than what shows up on the scale.

These medications are revealing a range of effects on the body that researchers are still working to fully understand. Some of these findings are already shaping how doctors prescribe these drugs. Others are still being studied. All of them are worth knowing about.

How GLP-1 Drugs Work Beyond Appetite

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. GLP-1 receptor agonists mimic this hormone, but their effects extend far beyond telling your brain you're full.

GLP-1 receptors exist throughout the body, including in the heart, kidneys, liver, lungs, and even the brain. That widespread distribution is a key reason why these drugs appear to produce effects in so many different organ systems.

Drugs like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (found in Mounjaro and Zepbound) activate these receptors in ways that influence inflammation, blood vessel function, insulin sensitivity, and more.

Cardiovascular Protection

This is the most well-established benefit beyond weight loss. The LEADER trial for liraglutide and the SUSTAIN-6 and SELECT trials for semaglutide have all demonstrated meaningful reductions in major cardiovascular events.

The SELECT trial, published in the New England Journal of Medicine in 2023, was particularly significant. It studied over 17,000 adults with obesity and established cardiovascular disease but without diabetes. Those taking semaglutide had a 20% lower risk of serious heart events like heart attack and stroke compared to placebo.

This wasn't just because patients lost weight. Researchers believe direct effects on blood vessel inflammation, blood pressure, and lipid levels all play a role.

What This Means for You

If you have a history of heart disease or multiple cardiovascular risk factors, this benefit may be an important part of the conversation with your doctor. The FDA has approved Wegovy specifically for reducing cardiovascular risk in adults with obesity or overweight who have established heart disease.

Kidney Health

Chronic kidney disease (CKD) affects roughly 37 million Americans, and it often develops alongside type 2 diabetes and obesity. New data suggests GLP-1 drugs may slow its progression significantly.

The FLOW trial, a large phase 3 study of semaglutide in patients with type 2 diabetes and CKD, was stopped early because the results were so clear. Semaglutide reduced the risk of serious kidney outcomes by about 24% compared to placebo. The FDA granted semaglutide a new indication for reducing kidney disease progression in adults with type 2 diabetes and CKD in 2024.

Researchers believe the drug's effects on blood pressure, blood sugar control, and inflammation in the kidneys all contribute to this benefit.

Liver Disease (MASLD)

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is the new name for what was previously called non-alcoholic fatty liver disease. It affects an estimated 25-30% of adults globally and is strongly linked to obesity and insulin resistance.

GLP-1 drugs appear to reduce liver fat accumulation and inflammation. Resmetirom (a separate liver-focused drug) recently became the first FDA-approved treatment specifically for MASH, the advanced form of MASLD. But semaglutide has also shown meaningful liver benefits in clinical trials.

A phase 3 trial called ESSENCE, investigating semaglutide in patients with MASH and liver fibrosis, reported in 2024 that semaglutide significantly improved liver histology (the structural health of liver tissue) compared to placebo.

Why This Matters

If you have been told you have fatty liver disease or elevated liver enzymes, mentioning this to your prescriber could make GLP-1 therapy an even more compelling option. Always discuss your full health history before starting any new medication.

Sleep Apnea

Obstructive sleep apnea is closely linked to excess body weight, so some improvement from weight loss alone is expected. But the results from the SURMOUNT-OSA trial were striking even beyond that connection.

This trial studied tirzepatide (the active ingredient in Mounjaro and Zepbound) in adults with moderate-to-severe obstructive sleep apnea and obesity. Participants saw a roughly 63% reduction in the apnea-hypopnea index (a measure of breathing disruptions during sleep) compared to about 6% in the placebo group.

The results led the FDA to approve Zepbound specifically for treating moderate-to-severe obstructive sleep apnea in adults with obesity in late 2024, making it the first medication approved for this condition.

Inflammation and Immune Function

One of the less-publicized areas of GLP-1 research involves the drugs' effects on systemic inflammation. Chronic low-grade inflammation is a driver of many serious diseases, including cardiovascular disease, certain cancers, and neurodegenerative conditions.

GLP-1 receptor activation appears to reduce levels of inflammatory markers like C-reactive protein (CRP) and various cytokines (signaling proteins involved in immune responses). This effect seems to occur independently of weight loss, which has sparked significant scientific interest.

Early-stage research is also exploring whether GLP-1 drugs might have a role in conditions like Parkinson's disease and Alzheimer's disease, given that inflammation plays a central role in both. These areas are still under investigation and no firm conclusions can be drawn yet, but clinical trials are ongoing.

Potential Effects on Alcohol and Substance Use

This is one of the more unexpected research frontiers. Several observational studies and early clinical investigations have found that people taking GLP-1 medications report reduced cravings for alcohol, cigarettes, and in some cases other substances.

The mechanism being studied relates to the dopamine reward pathways in the brain. GLP-1 receptors in the brain's reward centers may blunt the pleasurable response to addictive substances, reducing cravings.

Researchers at institutions including the National Institute on Alcohol Abuse and Alcoholism are studying this closely. Semaglutide is currently being investigated in clinical trials specifically for alcohol use disorder.

This research is early-stage and GLP-1 drugs are not approved for addiction treatment. But if you have struggled with alcohol or smoking alongside obesity, it's worth raising with your doctor.

Polycystic Ovary Syndrome (PCOS)

PCOS is a hormonal condition affecting roughly 1 in 10 women of reproductive age. It's associated with insulin resistance, weight gain, irregular periods, and fertility challenges.

Because GLP-1 medications improve insulin sensitivity and support weight loss, they are increasingly being studied and used off-label in women with PCOS. Some clinical data suggests improvements in menstrual regularity, androgen levels (male hormones that are elevated in PCOS), and metabolic markers.

GLP-1 drugs are not currently FDA-approved specifically for PCOS, but this is an active area of research and a growing reason why ob-gyns and endocrinologists are discussing these medications with patients.

What These Benefits Mean for Insurance and Cost

Here's where things get practical. Insurance coverage for GLP-1 medications has often been tied to specific approved indications. Historically, many plans covered these drugs for type 2 diabetes (under diabetes drug codes) but not for weight loss.

The expanding list of FDA approvals for cardiovascular risk reduction and sleep apnea is starting to change that calculus. If you have one of these newly recognized indications alongside obesity, your coverage options may be broader.

Knowing your full clinical picture before talking to a prescriber can help ensure you're accessing coverage you may already qualify for. You can also explore GLP-1 Coupons to reduce out-of-pocket costs regardless of your coverage situation.

Questions to Ask Your Doctor

If you're considering a GLP-1 medication or are already taking one, these questions can help you get the most out of your appointment.

• Do I have any of the conditions, like cardiovascular disease, CKD, or sleep apnea, that might make me eligible for a specific FDA approval?
• Could my health conditions affect which GLP-1 drug is the best fit for me?
• Are there any monitoring tests I should have, like kidney function or liver enzyme checks, before or during treatment?
• Does my insurance cover GLP-1 medications for any of the newer approved indications?
• Are there clinical trials for GLP-1 drugs that might be relevant to my situation?

Bringing a clear picture of your medical history to this conversation gives your prescriber the information they need to make the best recommendation.